Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference

Abstract Co-infection by human immunodeficiency virus and hepatitis B and C viruses is quite common because they share similar routes of transmission. The introduction of highly active antiretroviral therapy has significantly improved the life expectancy of HIV-infected patients in the last few years. However, chronic viral hepatitis represents an emerging cause of morbidity and mortality in this population, either as a result of end-stage liver disease or as a consequence of hepatotoxicity induced by antiretroviral drugs. The main goal of the Consensus Conference was to establish specific recommendations for the management of chronic viral hepatitis B and C in HIV-infected patients. The role of orthotopic liver transplantation for co-infected individuals with end-stage liver disease was also assessed.

[1]  P. Marcellin,et al.  Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing. , 2008, Liver.

[2]  M. Kazatchkine,et al.  Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients , 2001 .

[3]  J. González-lahoz,et al.  Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. , 2001, AIDS research and human retroviruses.

[4]  S. Sauleda,et al.  Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders , 2001, Hepatology.

[5]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[6]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Lafeuillade,et al.  Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection , 2001, The Lancet.

[8]  P. Gow,et al.  Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy. , 2001, AIDS.

[9]  A. Tamori,et al.  Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis , 2001, The Lancet.

[10]  L. Seeff,et al.  The Relationship of Acute Transfusion-Associated Hepatitis to the Development of Cirrhosis in the Presence of Alcohol Abuse , 2001, Annals of Internal Medicine.

[11]  S. Goodman,et al.  Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. , 2001, JAMA.

[12]  V. Soriano,et al.  Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C , 2001, American Journal of Gastroenterology.

[13]  P. Reiss,et al.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.

[14]  M. Puoti,et al.  Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. , 2000, Archives of internal medicine.

[15]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[16]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[17]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.

[18]  M. Diago,et al.  Retreatment for 24 vs 48 weeks with interferon‐α2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone , 2000, Journal of viral hepatitis.

[19]  D. Neau,et al.  Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient. , 2000, The Journal of infection.

[20]  M. Kazatchkine,et al.  Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. , 2000, AIDS.

[21]  K. Miller,et al.  Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases , 2000, Annals of Internal Medicine.

[22]  A. Lazzarin,et al.  Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. , 2000, AIDS.

[23]  Rey,et al.  Hepatitis C virus co‐infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus‐positive patients , 2000, Journal of viral hepatitis.

[24]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[25]  F. Donato,et al.  Mortality for liver disease in patients with HIV infection: a cohort study. , 2000, Journal of acquired immune deficiency syndromes.

[26]  R. Schvarcz,et al.  Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). , 2000, Transplantation.

[27]  J. Lang,et al.  Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. , 2000, Vaccine.

[28]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[29]  Ying,et al.  Lamivudine, adefovir and tenofovir exhibit long‐lasting anti‐hepatitis B virus activity in cell culture , 2000, Journal of viral hepatitis.

[30]  Z. Goodman,et al.  Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.

[31]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[32]  V. Soriano,et al.  Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. , 1999, Journal of acquired immune deficiency syndromes.

[33]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[34]  C. Katlama,et al.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.

[35]  D. Cooper,et al.  Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. , 1999, The Journal of infectious diseases.

[36]  D. Wolf,et al.  Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. , 1999, Transplantation.

[37]  G. Raimondo,et al.  Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. , 1999, The New England journal of medicine.

[38]  M. Velasco,et al.  Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. , 1999, The New England journal of medicine.

[39]  S. Lawrence,et al.  Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  C. Tsoukas,et al.  Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. , 1999, The Journal of infectious diseases.

[41]  J. García-Samaniego,et al.  Management of chronic hepatitis C in HIV-infected patients. , 1999, AIDS.

[42]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[43]  F. Mahoney,et al.  Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection , 1999, Clinical Microbiology Reviews.

[44]  J. Fung,et al.  Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. , 1999, Blood.

[45]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[46]  M. French,et al.  Hepatitis C virus‐associated hepatitis following treatment of HIV‐infected patients with HIV protease inhibitors: an immune restoration disease? , 1998, AIDS.

[47]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[48]  V. Vullo,et al.  Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. , 1998, AIDS.

[49]  J. Peña,et al.  Acute hepatitis in HIV-infected patients during ritonavir treatment. , 1998, AIDS.

[50]  V. Soriano,et al.  Hepatotoxicity after introduction of highly active antiretroviral therapy. , 1998, AIDS.

[51]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[52]  C. Sabin,et al.  Outcome of orthotopic liver transplantation in patients with haemophilia , 1998, Gut.

[53]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[54]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[55]  J. Castilla,et al.  Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. , 1998, Journal of hepatology.

[56]  J. Castilla,et al.  A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group. , 1997, The Journal of infection.

[57]  J. Castilla,et al.  Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. , 1997, The American journal of gastroenterology.

[58]  R. D. de Man,et al.  Lamivudine resistance inimmunocompetent chronic hepatitis B , 1997 .

[59]  D. Cooper,et al.  Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor , 1997, The Lancet.

[60]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[61]  H. Volk,et al.  Distribution of lymphocyte subtypes in liver transplant recipients. , 1997, Transplantation proceedings.

[62]  R. Tubiana,et al.  Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.

[63]  J. Castilla,et al.  Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus , 1996 .

[64]  A. Kirn,et al.  High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV , 1995, AIDS.

[65]  D. Vlahov,et al.  Correlates of Hepatitis C Virus Infections among Injection Drug Users , 1995, Medicine.

[66]  K. Hyams.  Risks of chronicity following acute hepatitis B virus infection: a review. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  J. Vicario,et al.  CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. HIV-Hepatitis Spanish Study Group. , 1994, AIDS.

[68]  D. Samuel,et al.  An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  V. Soriano,et al.  Significance of HCV RIBA‐2 Indeterminate Results in High‐Risk Individuals: Assessment by a New Third‐Generation RIBA Assay and PCR , 1994, Vox sanguinis.

[70]  T. Wright,et al.  Clinical aspects of hepatitis B virus infection , 1993, The Lancet.

[71]  M. Krajden,et al.  Hepatitis C virus infection in patients infected with the human immunodeficiency virus. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  J. Goedert,et al.  Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.

[73]  M. Mihatsch,et al.  THE EFFECT OF CYCLOSPORINE ON THE PROGRESSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION TRANSMITTED BY TRANSPLANTATION–DATA ON FOUR CASES AND REVIEW OF THE LITERATURE , 1993, Transplantation.

[74]  M. Bruguera,et al.  Impaired Response to Recombinant Hepatitis B Vaccine in HIV‐Infected Persons , 1992, Journal of clinical gastroenterology.

[75]  H. Balfour,et al.  Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. , 1991, Reviews of infectious diseases.

[76]  D. Cooper,et al.  The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. , 1991, The Journal of infectious diseases.

[77]  R. Perrillo,et al.  Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. , 1990, Gastroenterology.

[78]  T E Starzl,et al.  Transplantation in HIV+ patients. , 1990, Transplantation.

[79]  J. Hoofnagle,et al.  Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. , 1989, Gastroenterology.

[80]  R. Luzzati,et al.  CLINICAL REACTIVATION OF HEPATITIS B IN ANTI-HBs-POSITIVE PATIENTS WITH AIDS , 1989, The Lancet.

[81]  R. Tedder,et al.  Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. , 1988, AIDS.

[82]  J. Delfraissy,et al.  Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. , 1988, The Journal of infectious diseases.

[83]  R. Rubin,et al.  The problem of human immunodeficiency virus (HIV) infection and transplantation , 1988, Transplant international : official journal of the European Society for Organ Transplantation.

[84]  J. Harris,et al.  Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV‐III antibodies to recombinant α‐interferon , 1987, Hepatology.

[85]  R. Perrillo,et al.  Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. , 1986, Annals of internal medicine.

[86]  E. Gelmann,et al.  Hepatitis B virus infection in the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.

[87]  V. Soriano,et al.  Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users , 2004, European Journal of Epidemiology.

[88]  F. Callea,et al.  Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2001, The Journal of infectious diseases.

[89]  J. Palmisano,et al.  Lactic acidosis associated with stavudine administration: a report of five cases. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[91]  M. Ruiz-Navarro,et al.  Efecto del tratamiento antirretrovírico y de la profilaxis para enfermedades oportunistas en la supervivencia de los pacientes con SIDA , 2000 .

[92]  Eduardo Torroja y Miret,et al.  Hospital Clínico San Carlos. , 2000 .

[93]  A. Alberti,et al.  Natural history of hepatitis C. , 1999, Journal of hepatology.

[94]  V. Soriano,et al.  Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. , 1999, Journal of hepatology.

[95]  Willis C. Maddrey,et al.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. , 1999, Journal of hepatology.

[96]  M. Sulkowski,et al.  Viral hepatitis among injection drug users , 1998 .

[97]  M. Leal,et al.  Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. , 1997, Journal of hepatology.

[98]  C. Naylor,et al.  Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. , 1995, Gastroenterology.

[99]  V. Martín,et al.  Hepatitis B vaccination in prisons: the Catalonian experience. , 1993, Vaccine.

[100]  J. Nielsen,et al.  The influence of HTLV‐III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers , 1987, Hepatology.

[101]  V. Rustgi.  HEPATITIS B INFECTION IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME , 1984 .